Replimune Group (FRA:7R8) ROCE %: -101.91% (As of Mar. 2026)


FRA:7R8 Replimune Group Inc FRA:7R8
32 GF Score
Price €9.22
! 4 Warning Signs
View Full Analysis

What is Replimune Group ROCE %?

Replimune Group FRA:7R8 -3.56% 32 ROCE % is -101.91% as of Mar. 2026. GuruFocus rates FRA:7R8 with a GF Score™ of 32/100. The stock has 4 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Replimune Group's annualized ROCE % for the quarter that ended in Mar. 2026 was -101.91%.

Replimune Group  (FRA:7R8) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Replimune Group ROCE % Related Terms

Replimune Group ROCE % Historical Data

* Premium members only.

The historical data trend for Replimune Group's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Replimune Group ROCE % Chart

Replimune Group Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -24.92 -32.63 -39.04 -51.17 -76.69

Replimune Group Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -54.39 -72.73 -86.07 -89.48 -101.91
FRA:7R8
32GF Score
Replimune Group Inc FRA:7R8
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Replimune Group ROCE % Calculation

Replimune Group's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=-264.372/( ( (509.978 - 57.685) + (287.516 - 50.367) )/ 2 )
=-264.372/( (452.293+237.149)/ 2 )
=-264.372/344.721
=-76.69 %

Replimune Group's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-244.208/( ( (284.886 - 42.774) + (287.516 - 50.367) )/ 2 )
=-244.208/( ( 242.112 + 237.149 )/ 2 )
=-244.208/239.6305
=-101.91 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -101.91% mean?
Replimune Group (FRA:7R8) has a ROCE % of -101.91% as of Mar. 2026.
Is Replimune Group's ROCE % too high?
Replimune Group's current ROCE % is -101.91%. Overall, Replimune Group has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Replimune Group's ROCE % compare to AVTX and KURA?
Replimune Group's ROCE % of -101.91% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Replimune Group's current ROCE % is -101.91%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Replimune Group stock overvalued right now?
Replimune Group (FRA:7R8) has a current ROCE % of -101.91%. The current ROCE % is -101.91%. Replimune Group's overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Replimune Group (FRA:7R8), the current ROCE % is -101.91% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Replimune Group Business Description

Other Exchanges REPL:USA
Address 500 Unicorn Park Drive, Suite 303, 3rd Floor, Woburn, MA, USA, 01801
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
32GF Score

Get the complete analysis for FRA:7R8

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€9.22
Price